Clinical Trial Update: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating cannabidiol oral solution as adjunctive therapy for inadequately controlled Dravet syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome

Drugs mentioned

• Cannabidiol Oral Solution (cannabidiol)

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Dravet Syndrome | Phase 3 | Status: WITHDRAWN